A newborn infected with RSV is at low risk of serious bacterial infection

Octavio Ramilo, MD, joins us once again to discuss potential benefits of RSV vaccination beyond disease prevention, and to explain how to speak with patients about vaccines and uptake.

The news is full of stories about monkeypox, the recent changes to COVID-19 guidance, and the return of polio cases. What do clinicians need to know?

Glecaprevir/pibrentasvir was a "highly efficacious treatment for people with acute HCV," with 96.2% of patients analyzed having sustained virological response 12 weeks post-treatment.

Contemporary Pediatrics sat down with Tina Q. Tan, MD, FAAP, FIDSA, FPIDS, to discuss what's known about the variant. She also discusses the latest on the vaccine for children aged younger than 5 years.

Six-month results from the phase 2 VLA1553-221 trial aligned with initial data and demonstrated immune response at day 180 among patients aged 1 to 11 years.

The data found complements state- and national-level CDC data, confirming widespread declines in MMR vaccination rates.